Beam Therapeutics, Inc. (BEAM)
NASDAQ:BEAM
Want to see BEAM full AI Analyst Report?
Top Page
Beam Therapeutics
(NASDAQ:BEAM)
Select Model
Select Model
Rating:62Neutral
Price Target:
$28.00
▼(-10.80% Downside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by weak financial performance driven by heavy cash burn and ongoing losses, despite a solid balance-sheet profile for an early-stage biotech. Offsetting this, technicals are constructive (price above major moving averages with positive momentum), and the earnings call highlighted strong pipeline progress plus extended runway from substantial cash and a large non-dilutive financing facility. Valuation contributes less due to a negative P/E and no dividend.
Positive Factors
Extended Cash Runway and Non-dilutive Financing
A strong cash position plus a milestone-linked $500M facility materially reduces near- and medium-term financing risk, supporting multiple IND/BLA milestones without immediate dilution. This preserves strategic optionality to advance programs through clinical inflection points and potential commercialization planning.
Negative Factors
Substantial Negative Cash Flow
Persistent, large negative operating and free cash flows mean the company remains reliant on external funding to sustain operations and advance multiple programs. Even with current cash and facilities, sustained burn risks funding gaps if milestones slip or conditional financing tranches are not achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended Cash Runway and Non-dilutive Financing
A strong cash position plus a milestone-linked $500M facility materially reduces near- and medium-term financing risk, supporting multiple IND/BLA milestones without immediate dilution. This preserves strategic optionality to advance programs through clinical inflection points and potential commercialization planning.
Read all positive factors
Beam Therapeutics (BEAM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.76B
Dividend YieldN/A
Average Volume (3M)2.15M
Price to Earnings (P/E)―
Beta (1Y)2.25
Revenue Growth157.97%
EPS Growth86.11%
CountryUS
Employees393
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.64
Shares Outstanding102,879,210
10 Day Avg. Volume2,212,221
30 Day Avg. Volume2,152,781
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.21
Price to Sales (P/S)19.62
P/FCF Ratio-7.61
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue16.78
Enterprise Value/Gross Profit-51.74
Enterprise Value/Ebitda-43.82
Forecast
1Y Price Target
$49.91Price Target Upside59.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-4.42
Revenue Forecast (FY)$70.79M
Beam Therapeutics Business Overview & Revenue Model
Company Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassem...
How the Company Makes Money
Beam Therapeutics makes money primarily through (1) collaboration and licensing revenue from strategic partnerships and (2) operating cash and investment income; it may also generate smaller amounts of other revenue (e.g., grants) depending on the...
Beam Therapeutics Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call presented substantial positive momentum: a new liver-targeted PKU program with strong preclinical efficacy, constructive FDA engagement around an umbrella platform approach, demonstrated LNP and manufacturing capabilities, and a major non-dilutive financing that extends runway into mid-2029. Key risks highlighted include regulatory ambiguity for novel individualized pathways, the large diversity of PAH variants (necessitating personalized approaches), limited public detail on bystander/off-target profiles, and conditional milestone-based financing. On balance, the updates emphasize progress, resources, and clear near-term milestones while acknowledging technical and regulatory uncertainties that are typical for platform-based gene editing development.Positive Updates
New PKU Program (BEAM-304) Initiated and Rapidly Advanced
Beam announced BEAM-304, a liver-targeted base editing program for phenylketonuria (PKU). The company identified two development candidates (including R408W) that together could treat nearly half (~50%) of PKU patients in the U.S. Initial IND-enabling work was advanced in under 2 years with an IND planned to be filed in 2026.
Negative Updates
Regulatory Ambiguity Around 'Plausible Mechanism' Pathway
Draft FDA guidance on the plausible mechanism pathway remains ambiguous about which diseases/variants qualify (ultra-rare vs. more common variants). Beam indicated the framework could help but final applicability to PKU (with both frequent and ultra-rare variants) is uncertain and will require case-by-case discussions with regulators.
Read all updates
Q4-2025 Updates
Positive
Negative
New PKU Program (BEAM-304) Initiated and Rapidly Advanced
Beam announced BEAM-304, a liver-targeted base editing program for phenylketonuria (PKU). The company identified two development candidates (including R408W) that together could treat nearly half (~50%) of PKU patients in the U.S. Initial IND-enabling work was advanced in under 2 years with an IND planned to be filed in 2026.
Read all positive updates
Company Guidance
Beam provided clear program and financial guidance: Beam plans to file the BEAM‑304 IND in 2026 and initiate an open‑label, single‑ascending‑dose Phase I/II in R408W, expects to report updated BEAM‑302 Phase I/II data and a pivotal plan this quarter and to submit the risto‑cel BLA as early as year‑end 2026, and also expects to report initial BEAM‑301 GSDIa data, complete the BEAM‑103 healthy volunteer study and advance in‑vivo HSC editing during 2026. Financially, Beam ended 2025 with $1.25 billion in cash/cash equivalents/marketable securities and announced a Sixth Street facility up to $500 million ( $100M funded at close, up to $300M tied to regulatory/clinical/commercial milestones, plus $100M subject to mutual agreement over a 7‑year term), with a minimum draw of $200M expected to extend runway into mid‑2029 and principal repayment due early 2033. Key program metrics highlighted include two BEAM‑304 candidates that could address nearly half of ~20,000 U.S. PKU patients, preclinical single‑dose (0.3 mg/kg) LNP results that normalized plasma phenylalanine below the 360 µM therapeutic threshold by day 7 in R408W and a second mutation model, and recognition of >1,000 PAH variants worldwide supporting an umbrella/multi‑variant IND approach.Beam Therapeutics Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
74
Positive
Cash Flow
29
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 164.01M | 139.74M | 63.52M | 377.71M | 60.92M | 51.84M |
| Gross Profit | -53.18M | 117.45M | -304.04M | 377.71M | -250.67M | -180.29M |
| EBITDA | -62.79M | -29.92M | -393.64M | -146.95M | -324.33M | -230.06M |
| Net Income | -65.04M | -79.99M | -376.74M | -132.53M | -289.09M | -370.64M |
Balance Sheet | ||||||
| Total Assets | 1.48B | 1.48B | 1.10B | 1.46B | 1.34B | 1.47B |
| Cash, Cash Equivalents and Short-Term Investments | 1.21B | 1.25B | 850.74M | 1.19B | 1.08B | 965.65M |
| Total Debt | 250.82M | 293.88M | 161.43M | 172.69M | 179.00M | 147.64M |
| Total Liabilities | 316.36M | 242.82M | 370.28M | 478.38M | 608.24M | 647.72M |
| Stockholders Equity | 1.16B | 1.24B | 733.54M | 981.33M | 733.47M | 826.74M |
Cash Flow | ||||||
| Free Cash Flow | -383.84M | -360.05M | -356.19M | -182.93M | -26.42M | -113.08M |
| Operating Cash Flow | -369.73M | -345.10M | -347.25M | -149.19M | 22.53M | -66.27M |
| Investing Cash Flow | 28.92M | -121.44M | 185.01M | 71.84M | -461.34M | -294.14M |
| Financing Cash Flow | 101.28M | 478.05M | 7.74M | 276.45M | 111.59M | 756.14M |
Beam Therapeutics Technical Analysis
Negative
31.39
Price Trends
27.69
Negative
28.24
Negative
25.60
Positive
Market Momentum
>-0.01
Positive
39.46
Neutral
4.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BEAM, the sentiment is Negative. The current price of 31.39 is above the 20-day moving average (MA) of 30.00, above the 50-day MA of 27.69, and above the 200-day MA of 25.60, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.46 is Neutral, neither overbought nor oversold. The STOCH value of 4.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BEAM.
Beam Therapeutics Risk Analysis
Beam Therapeutics disclosed 87 risk factors in its most recent earnings report. Beam Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Beam Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $2.51B | -67.46 | -1.41% | ― | 95.29% | 98.21% | |
62 Neutral | $2.76B | -6.52 | -5.89% | ― | 157.97% | 86.11% | |
62 Neutral | $5.40B | -10.43 | -65.80% | ― | ― | -2.53% | |
58 Neutral | $1.44B | 29.49 | -4.83% | ― | 23.64% | -29.23% | |
52 Neutral | $2.92B | -6.97 | -52.20% | ― | ― | -7.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $2.55B | -9.69 | -36.95% | ― | ― | -68.57% |
* Healthcare Sector Average
BEAM
Beam Therapeutics
26.33
9.11
52.90%
DNLI
Denali Therapeutics
18.11
4.42
32.29%
IMVT
Immunovant
26.29
11.88
82.44%
ARQT
Arcutis Biotherapeutics
19.50
5.74
41.72%
IRON
Disc Medicine
64.07
15.18
31.05%
IMCR
Immunocore Holdings
28.93
-2.73
-8.62%
Beam Therapeutics Corporate Events
Business Operations and Strategy
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit
Positive
Mar 5, 2026
On March 2, 2026, Beam Therapeutics Inc. and Japan-based Bio Palette Co., Ltd. mutually terminated their 2019 cross-license agreement covering base-editing and gene-editing patents, in connection with the planned dissolution of Bio Palette. Under ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Beam Therapeutics Secures $500 Million Credit Facility
Positive
Feb 24, 2026
On February 24, 2026, Beam Therapeutics reported fourth-quarter and full-year 2025 financial results, showing cash, cash equivalents and marketable securities of $1.25 billion at year-end, up from $850.7 million a year earlier, alongside higher an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.